A noninferiority cluster-randomized controlled trial on antibiotic postprescription review and authorization by trained general pharmacists and infectious disease clinical fellows

Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America
Pinyo RattanaumpawanVisanu Thamlikitkul

Abstract

We compared the effectiveness of antibiotic postprescription review and authorization (PPRA) determined by infectious disease (ID) clinical fellows with that of trained general pharmacists. We conducted a noninferiority cluster-randomized controlled trial in 6 general medical wards at Siriraj Hospital in Bangkok, Thailand. Three wards were randomly assigned to the intervention (ie, the pharmacist PPRA group), and another 3 wards were assigned to the control (ie, the fellow PPRA group). We enrolled all patients in the study wards who received 1 or more doses of the targeted antibiotics: piperacillin/tazobactam, imipenem/cilastatin, and meropenem. The noninferiority margin was 10% for the favorable clinical response and 1.5 defined daily doses (DDDs) for the targeted antibiotics. We enrolled 303 patients in the pharmacist PPRA group and 307 patients in the ID fellow PPRA group. The baseline and clinical characteristics were similar in the 2 groups. The difference in the favorable response of patients who received the targeted antibiotics (ie, the pharmacist PPRA group minus the fellow PPRA group) was 5.15% (95% confidence interval [CI], -2.69% to 12.98%); the difference in the DDD of targeted antibiotic use (ie, the pharmacist PP...Continue Reading

Associated Clinical Trials

References

Jul 5, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R GrossN O Fishman
Oct 9, 2003·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Sujata M BhavnaniJerome J Schentag
Feb 24, 2006·Emerging Infectious Diseases·Peter DaveyMark Wilcox
Mar 18, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert C Owens, Louis Rice
Dec 19, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Timothy H DellitUNKNOWN Society for Healthcare Epidemiology of America
Aug 19, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Louis ValiquetteJacques Pépin
Oct 24, 2007·Pharmacotherapy·Michael J Rybak
Apr 3, 2008·Expert Review of Anti-infective Therapy·Dimple PatelB Joseph Guglielmo
Nov 11, 2008·Diagnostic Microbiology and Infectious Disease·Min-Hyok JeonYang Soo Kim
Mar 16, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Julia MoodyKavita K Trivedi
Mar 8, 2016·The Lancet Infectious Diseases·Emelie C SchutsJan M Prins
Apr 16, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Tamar F BarlamKavita K Trivedi

❮ Previous
Next ❯

Citations

May 4, 2021·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Pinyo RattanaumpawanVisanu Thamlikitkul

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.